Skip to Main Content

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Conditions

Genetics - Adult | Genetics - Pediatric

Phase III

What is the purpose of this trial?

Brief Summary:

This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF), including but not limited to those who are heterozygous for the F508del mutation

  • Trial with
    Vertex Pharmaceuticals Incorporated
  • Start Date
    09/16/2018
  • End Date
    04/23/2021
Trial Image

For more information about this study, contact:

Catalina Guzman

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/20/2018
  • Study HIC
    #2000022968